This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Dixon S, Peters JR.Evaluating the real cost-effectiveness of health technology: reconciling the public interest with patients' interests. Current Medical Research and Opinion 23 (Spec. issue 1): 1-6, 2007
McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ.Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Current Medical Research and Opinion 23 (Spec. issue 1): 7-19, 2007
McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ.Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Current Medical Research and Opinion 23 (Spec. issue 1): 21-31, 2007
Currie CJ, Poole CD, Tetlow T, Holmes P, McEwan P.The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Current Medical Research and Opinion 23 (Suppl. 1): 33-39, 2007
Poole CD, Tetlow T, McEwan P, Holmes P, Currie CJ.The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Current Medical Research and Opinion 23 (Spec. issue 1): 41-46, 2007
Rights and permissions
About this article
Cite this article
Insulin glargine adds up to value for diabetes in the UK. Pharmacoecon. Outcomes News 528, 3–4 (2007). https://doi.org/10.2165/00151234-200705280-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705280-00004